Sunshine Heart, Inc. (SSH,SHC.AX) said it has received conditional approval from the FDA for its next generation C-Pulse System driver. This new iteration is designed to provide moderate to severe heart failure patients with enhanced patient comfort and performance.
The new driver features a single unit which is lighter, quieter and approximately half the size of its predecessor and also features a number of software enhancements.
Conditional approval from the FDA allows the company to use this next generation driver for investigational purposes in the U.S. at all sites that are currently enrolled in Sunshine Heart's North American feasibility trial. Sunshine Heart plans to provide the C-Pulse driver to all patients currently on its C-Pulse device at all U.S. sites upon Institutional Review Board approval. This second generation driver is also expected to be used in the Company's future U.S. pivotal trial once the FDA has approved the company's investigational device exemption, or IDE, as well as in Europe.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.